Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Philadelphia Chromosome Negative, BCR-ABL1 Positive Chronic Myelogenous Leukemia”

78 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 78 results

Post-approval studies (Phase 4)Study completedNCT00171899
What this trial is testing

Study Comparing Standard Dose and High-dose Imatinib Mesylate in Patients With Chronic Phase Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML)

Who this might be right for
Chronic Myelogenous Leukemia
Novartis Pharmaceuticals 80
Early research (Phase 1)Study completedNCT00351975
What this trial is testing

Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases

Who this might be right for
Accelerated Phase of DiseaseAdult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11+17 more
National Cancer Institute (NCI) 56
Testing effectiveness (Phase 2)Study completedNCT00006475
What this trial is testing

STI571 in Treating Patients With Chronic Myelogenous Leukemia in Blast Crisis

Who this might be right for
Leukemia
Novartis
Testing effectiveness (Phase 2)Study completedNCT00769327
What this trial is testing

Nilotinib and Imatinib Mesylate in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia

Who this might be right for
Leukemia
Gruppo Italiano Malattie EMatologiche dell'Adulto 129
Testing effectiveness (Phase 2)Looking for participantsNCT04925479
What this trial is testing

Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia

Who this might be right for
Myeloid Leukemia, Philadelphia Positive
Novartis Pharmaceuticals 34
Testing effectiveness (Phase 2)Study completedNCT00006053
What this trial is testing

STI571 in Treating Patients With Chronic Myelogenous Leukemia That Has Not Responded to Interferon Alfa

Who this might be right for
Leukemia
Novartis
Large-scale testing (Phase 3)UnknownNCT00025402
What this trial is testing

Chemotherapy and Biological Therapy With or Without Bone Marrow or Peripheral Stem Cell Transplant in Treating Patients With Chronic Myelogenous Leukemia

Who this might be right for
Leukemia
III. Medizinische Klinik Mannheim 1,000
Testing effectiveness (Phase 2)Ended earlyNCT02629692
What this trial is testing

Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies

Who this might be right for
Healthy (For Part A)Chronic Myeloid Leukemia (for Part B and C)
Sun Pharma Advanced Research Company Limited 124
Large-scale testing (Phase 3)Ended earlyNCT02108951
What this trial is testing

Study to Assess Efficacy and Safety of Nilotinib 300mg Twice Daily in Patients With Philadelphia Positive Chronic Myeloid Leukaemia (CML) in Chronic Phase Who Are Intolerant to Prior Tyrosine Kinase Inhibitors.

Who this might be right for
Philidelphia Positive Chronic Myeloid Leukaemia
Novartis Pharmaceuticals 20
Large-scale testing (Phase 3)UnknownNCT00297570
What this trial is testing

Imatinib Versus Imatinib and Peg-Interferon in Patients With Ph+ CML and Complete Cytogenetic Response After Imatinib Therapy

Who this might be right for
Leukemia, Myeloid, Philadelphia-Positive
Sheba Medical Center 90
Early research (Phase 1)Study completedNCT00316953
What this trial is testing

Dasatinib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate

Who this might be right for
Accelerated Phase Chronic Myelogenous LeukemiaBlastic Phase Chronic Myelogenous LeukemiaChildhood Chronic Myelogenous Leukemia+5 more
National Cancer Institute (NCI) 48
Testing effectiveness (Phase 2)Ended earlyNCT04216563
What this trial is testing

ABL001 for the Treatment of Chronic Myeloid Leukemia in Patients Who Are on Therapy With Tyrosine Kinase Inhibitor

Who this might be right for
Philadelphia Chromosome Negative, BCR-ABL1 Positive Chronic Myelogenous Leukemia
M.D. Anderson Cancer Center 7
Testing effectiveness (Phase 2)Study completedNCT03578367
What this trial is testing

Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.

Who this might be right for
CMLChronic Myelogenous LeukemiaLeukemia, Myeloid Chronic+1 more
Novartis Pharmaceuticals 104
Testing effectiveness (Phase 2)Study completedNCT01274351
What this trial is testing

Study of Nilotinib as First Line Treatment in Philadelphia Chromosome Positive(Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)

Who this might be right for
Chronic Myelogenous Leukemia
Novartis Pharmaceuticals 112
Post-approval studies (Phase 4)Study completedNCT01227577
What this trial is testing

CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib

Who this might be right for
Chronic Myelogenous Leukemia in Chronic Phase
Novartis Pharmaceuticals 128
Testing effectiveness (Phase 2)Study completedNCT00481052
What this trial is testing

Nilotinib as First-line Treatment of Ph+ CML in Early Chronic Phase

Who this might be right for
Chronic Myeloid Leukemia
Gruppo Italiano Malattie EMatologiche dell'Adulto 74
Not applicableNo Longer AvailableNCT04518644
What this trial is testing

Nilotinib, for Patients With CML-CP or CML-AP

Who this might be right for
Chronic Myelogenous Leukemia (CML)
Novartis Pharmaceuticals
Testing effectiveness (Phase 2)Looking for participantsNCT07354074
What this trial is testing

Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP

Who this might be right for
Chronic Myelogenous LeukemiaLeukemia, Myelogenous, Chronic, Philadelphia Chromosome Positive
Novartis Pharmaceuticals 50
Not applicableUnknownNCT01564836
What this trial is testing

Discontinuation Study of Imatinib in Adult CP CML Patients Who Have a Complete Molecular Response to Imatinib

Who this might be right for
Chronic Myeloid LeukemiaImatinibComplete Molecular Response
Seoul St. Mary's Hospital 50
Testing effectiveness (Phase 2)Study completedNCT00006052
What this trial is testing

STI571 in Treating Patients With Accelerated Phase Chronic Myelogenous Leukemia

Who this might be right for
Leukemia
Novartis
Next Page